Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INCRNASDAQ:LPCNNASDAQ:MISTNASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINCRInterCure$1.60$1.46$1.17▼$3.40$72.92M1.2531,179 shs3,035 shsLPCNLipocine$3.35+1.4%$3.23$2.75▼$11.79$17.90M1.5231,684 shs10,352 shsMISTMilestone Pharmaceuticals$1.20-7.4%$1.35$0.63▼$2.75$63.89M0.86864,523 shs2.18 million shsPYXSPyxis Oncology$1.09+1.4%$1.05$0.83▼$5.39$67.21M1.15735,375 shs497,919 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINCRInterCure-0.31%+0.70%+20.99%-9.43%-50.78%LPCNLipocine+2.64%-0.30%+16.20%-12.70%-34.13%MISTMilestone Pharmaceuticals+0.39%-2.65%+88.39%-41.32%-26.15%PYXSPyxis Oncology-0.47%-3.18%+11.31%-27.55%-75.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINCRInterCure0.8721 of 5 stars0.05.00.00.02.00.00.6LPCNLipocine2.418 of 5 stars3.55.00.00.01.80.00.6MISTMilestone Pharmaceuticals1.6998 of 5 stars3.22.00.00.02.71.70.0PYXSPyxis Oncology1.3053 of 5 stars3.41.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINCRInterCure 0.00N/AN/AN/ALPCNLipocine 3.00Buy$10.00198.95% UpsideMISTMilestone Pharmaceuticals 2.40Hold$17.001,322.59% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00729.49% UpsideCurrent Analyst Ratings BreakdownLatest LPCN, PYXS, INCR, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/19/2025PYXSPyxis OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/17/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINCRInterCure$238.85M0.31N/AN/A$2.72 per share0.59LPCNLipocine$11.20M1.60N/AN/A$3.83 per share0.87MISTMilestone Pharmaceuticals$1M63.89N/AN/A$0.50 per share2.39PYXSPyxis Oncology$16.15M4.16N/AN/A$2.81 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/ALPCNLipocine-$16.35M-$0.01N/A∞N/AN/A-19.17%-17.60%5/8/2025 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$0.68N/AN/AN/AN/A-151.82%-49.85%5/12/2025 (Estimated)PYXSPyxis Oncology-$73.79M-$1.30N/AN/AN/AN/A-36.22%-28.76%5/13/2025 (Estimated)Latest LPCN, PYXS, INCR, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PYXSPyxis Oncology-$0.29N/AN/AN/AN/AN/A5/12/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19N/AN/AN/AN/AN/A5/7/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million3/18/2025Q4 2024PYXSPyxis Oncology-$0.33-$0.32+$0.01-$0.60N/A$16.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINCRInterCureN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINCRInterCure0.151.781.15LPCNLipocineN/A12.9712.97MISTMilestone Pharmaceuticals2.1815.4015.40PYXSPyxis OncologyN/A7.337.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINCRInterCure8.34%LPCNLipocine9.11%MISTMilestone Pharmaceuticals86.18%PYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipINCRInterCure0.24%LPCNLipocine6.12%MISTMilestone Pharmaceuticals9.90%PYXSPyxis Oncology9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINCRInterCure35045.57 million45.46 millionOptionableLPCNLipocine105.35 million5.02 millionNo DataMISTMilestone Pharmaceuticals3053.46 million48.05 millionOptionablePYXSPyxis Oncology6061.95 million53.64 millionOptionableLPCN, PYXS, INCR, and MIST HeadlinesRecent News About These CompaniesPyxis Oncology (PYXS) to Release Earnings on TuesdayMay 8 at 10:33 AM | marketbeat.comNew Approaches to Tumor Targeting Are Driving the Next Wave of Oncology BreakthroughsMay 8 at 3:54 AM | baystreet.caBoothbay Fund Management LLC Sells 201,674 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)May 5 at 4:43 AM | marketbeat.comPyxis Oncology reveals promising preclinical data for cancer drugApril 27, 2025 | investing.comPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADCApril 25, 2025 | globenewswire.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23, 2025 | zacks.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by AnalystsApril 18, 2025 | marketbeat.comTop Cancer Stocks to Buy to Boost Your Portfolio's HealthApril 16, 2025 | zacks.comPyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025March 25, 2025 | globenewswire.comStifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)March 24, 2025 | markets.businessinsider.comRBC Capital Remains a Buy on Pyxis Oncology (PYXS)March 20, 2025 | markets.businessinsider.comPyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)March 19, 2025 | markets.businessinsider.comPyxis Oncology (PYXS) Gets a Hold from William BlairMarch 19, 2025 | markets.businessinsider.comPyxis Oncology Advances Cancer Therapeutics with MICVOMarch 18, 2025 | tipranks.comPyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track DesignationMarch 18, 2025 | quiverquant.comPyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 18, 2025 | globenewswire.comPyxis Oncology to Participate at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comPyxis Oncology granted Fast Track designation for PYX-201 monotherapyFebruary 26, 2025 | markets.businessinsider.comPyxis Oncology rises on FDA fast track tag for lead assetFebruary 26, 2025 | msn.comPyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck CancerFebruary 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industry Behemoths Are Rewarding Investors With Dividend BumpsBy Leo Miller | April 28, 2025View 3 Industry Behemoths Are Rewarding Investors With Dividend BumpsAlphabet Rebounds After Strong Earnings and Buyback AnnouncementBy Ryan Hasson | April 28, 2025View Alphabet Rebounds After Strong Earnings and Buyback AnnouncementDisney Stock Jumps on Earnings—Is the Magic Sustainable?By Chris Markoch | May 7, 2025View Disney Stock Jumps on Earnings—Is the Magic Sustainable?3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomCoca-Cola Company Stock Can Bubble to New Highs This YearBy Thomas Hughes | April 29, 2025View Coca-Cola Company Stock Can Bubble to New Highs This YearLPCN, PYXS, INCR, and MIST Company DescriptionsInterCure NASDAQ:INCR$1.60 0.00 (0.00%) Closing price 03:37 PM EasternExtended Trading$1.58 -0.02 (-1.25%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Lipocine NASDAQ:LPCN$3.34 +0.05 (+1.36%) Closing price 03:58 PM EasternExtended Trading$3.23 -0.11 (-3.35%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Milestone Pharmaceuticals NASDAQ:MIST$1.20 -0.10 (-7.36%) Closing price 03:58 PM EasternExtended Trading$1.20 +0.00 (+0.42%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Pyxis Oncology NASDAQ:PYXS$1.08 +0.02 (+1.40%) Closing price 03:59 PM EasternExtended Trading$1.09 +0.01 (+0.46%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
